80 related articles for article (PubMed ID: 19804327)
1. Perindopril: beyond lowering blood pressure.
Zaiem A; Zannad F
Future Cardiol; 2008 May; 4(3):219-35. PubMed ID: 19804327
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
3. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
4. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
5. Evidence for benefits of perindopril in hypertension and its complications.
Laurent S
Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
7. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
[TBL] [Abstract][Full Text] [Related]
8. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
Leenen FH
Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
[TBL] [Abstract][Full Text] [Related]
10. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
11. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Curran MP; McCormack PL; Simpson D
Drugs; 2006; 66(2):235-55. PubMed ID: 16451098
[TBL] [Abstract][Full Text] [Related]
12. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
Mackay JA
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
[TBL] [Abstract][Full Text] [Related]
13. PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
J Hypertens Suppl; 1996 Dec; 14(6):S47-51. PubMed ID: 9023716
[TBL] [Abstract][Full Text] [Related]
14. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
[TBL] [Abstract][Full Text] [Related]
15. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
17. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
[TBL] [Abstract][Full Text] [Related]
18. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
19. A review of Perindopril in the reduction of cardiovascular events.
Campbell DJ
Vasc Health Risk Manag; 2006; 2(2):117-24. PubMed ID: 17319455
[TBL] [Abstract][Full Text] [Related]
20. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
